Fundz

CervoMed Appoints Dr. Matthew Winton as Chief Commercial and Business Officer

PUBLIC · CRVOOct 07, 2025

Position

Chief Commercial Officer

Company

CervoMed

Matthew Winton
BostonBiotechnologyHealthcareHealth Care

Description

CervoMed has announced the appointment of Dr. Matthew Winton as Chief Commercial and Business Officer. Dr Winton brings extensive experience to the role, having previously served as COO at Inozyme Pharma and held senior leadership positions at Biogen.

Quick answer

CervoMed Appoints Dr. Matthew Winton as Chief Commercial and Business Officer (October 7, 2025). CervoMed is based in Boston, Massachusetts, United States.

Who is the new Chief Commercial Officer at CervoMed?
CervoMed named Matthew Winton Chief Commercial Officer, announced October 7, 2025.
What did CervoMed announce on October 7, 2025?
CervoMed has announced the appointment of Dr. Matthew Winton as Chief Commercial and Business Officer. Dr Winton brings extensive experience to the role, having previously served as COO at Inozyme Pharma and held senior leadership positions at Biogen.
What does CervoMed do?
CervoMed is a public, Boston, MA-based company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases.
Where is CervoMed based?
CervoMed is based in Boston, Massachusetts, United States.
Which similar companies made leadership changes around the same time?
Sera Prognostics (October 1, 2025), Climb Bio, Inc. (October 1, 2025), Rockwell Medical (September 30, 2025) and Interwell Health (September 18, 2025) also announced leadership changes within 45 days of CervoMed.

Source: Fundz verified event record.

Other recent leadership changes in Healthcare and Biotechnology

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at CervoMed, and when

A new leader at CervoMed brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day CervoMed raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at CervoMed, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at CervoMed. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

CervoMed

Location

20 Park Plaza

Boston, Massachusetts, United States

About

CervoMed is a public, Boston, MA-based company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases. CervoMed was launched in 2014 as EIP Pharma, Inc, by R&D executives from the pharmaceutical and biotech industry.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment CervoMed changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for CervoMed's next move

Learn about Strategic plan

CervoMed changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.